Pharmacotherapy of chronic asthma

Drugs of Today

Volumn 35, Issue 8, 1999, Pages 605-619

  Lemanske Jr , Robert F ^a  

^a University of Wisconsin Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CIPROFLOXACIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; FORMOTEROL; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; METHYLXANTHINE; NEDOCROMIL; ORAL CONTRACEPTIVE AGENT; ORCIPRENALINE; PHENOBARBITAL; PHENYTOIN; PIRBUTEROL; RIFAMPICIN; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ADVERSE DRUG REACTION; ASTHMA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; FOOD DRUG INTERACTION; HUMAN; PRACTICE GUIDELINE; REVIEW; TREATMENT PLANNING;

EID: 0344563443     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.8.552217     Document Type: Review

References (125)

1. Lenfant, C., Khaltaev, N. Global initiative for asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report 1, 1993.
2. Murphy, S., Bleecker, E.R., Boushey, H. et al. Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program, II. National Institutes of Health: Bethesda 1997.
3. Sheffer, A.L. Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute National Asthma Education Program Expert Panel Report. J Allergy Clin Immunol 1992, 88(3, Pt 2): 425-534.
4. Gern, J.E., Lemanske, R.F. Jr. Beta-adrenergic agonist therapy. In: Immunology and Allergy Clinics of North America, Vol. 4. R.K. Bush (Ed.). W.B. Saunders Co.: Philadelphia 1993, 839-60.
5. Nelson, H.S. Drug therapy: Beta-adrenergic bronchodilators. New Engl J Med 1995, 333: 499-506.
6. Cockcroft, D.W., Murdock, K.Y. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987, 79: 734-40.
7. Howarth, P.M., Durham, S.R., Lee, T.H., Kay, A.B., Church, M.K., Holgate, S.T. Influence of albuterol, cromolyn sodium, and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985, 132: 986-92.
8. Sly, R.M., Heimlich, E.M., Busser, R.J., Strick, L. Exercise-induced bronchospasm: Evaluation of isoproterenol, phenylephrine and the combination. Ann Allergy 1967, 25: 324-30.
9. Lai, C.K.W., Twentyman, O.P., Holgate, S.T. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in non-specific bronchial responsiveness. Am Rev Respir Dis 1989, 140: 917-23.
10. Twentyman, O.P., Finnerty, J.P., Harris, A., Palmer, J., Holgate, S.T. Protection against allergen-induced asthma by salmeterol. Lancet 1990, 336: 1338-42.
11. Green, C.P., Price, J.F. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992, 67: 1014-7.
12. Palmqvist, M., Persson, G., Lazer, L., Rosenborg, I., Larsson, P., Lotvall, J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J 1997, 10: 2484-9.
13. Sears, M.R., Taylor, D.R., Print, C.G. et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990, 336: 1391-6.
14. Spitzer, W.O., Suissa, S., Ernst, P. et al. The use of β-agonists and the risk of death and near death from asthma. New Engl J Med 1992, 326: 501-6.
15. McFadden, E.R. Jr. Perspectives in β-2-agonist therapy: Vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol 1995, 95: 641-51.
16. Drazen, J.M., Israel, E., Boushey, H.A. et al. Comparison of regularly scheduled with asneeded use of albuterol in mild asthma. New Engl J Med 1996, 335: 841-7.
17. Pearlman, D.S., Chervinsky, P., LaForce, C. et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. New Engl J Med 1992, 327: 1420-5.
18. Steffensen, I., Faurschou, P., Riska, H., Rostrup, J., Wegener, T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Eur J Allergy Clin Immunol 1995, 50: 657-63.
19. Kozlik-Feldmann, R., Berdel, D., Reinhardt, D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and β-adrenoceptor density on lymphocytes in children with bronchial asthma. Eur J Med Res 1996, 1: 465-70.
20. Bhagat, R., Kaira, S., Swystun, V.A., Cockroft, D.W. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995, 108: 1235-9.
21. Bhagat, R., Swystun, V.A., Cockcroft, D.W. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: Dose response. J Allergy Clin Immunol 1996, 97: 47-52.
22. Boulet, L.-P., Cartier, A., Milot, J., Maio, J.-L., Laviolette, M. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: Influence of inhaled corticosteroids. Eur Respir J 1998, 11: 1091-7.
23. Giannini, D., Carietti, A., Dente, F.L. et al. Tolerance to the protective effect of salmeterol on allergen challenge. Chest 1996, 110: 1452-7.
24. Lipworth, B., Tan, S., Devlin, M., Aiken, T., Baker, R., Hendrick, D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998, 104: 431-8.
25. Peel, E.T., Gibson, G.J. Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine. Am Rev Respir Dis 1980, 121: 973-8.
26. Simons, F.E.R., Gerstner, T.V., Cheang, M.S. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997, 99: 655-9.
27. Kalra, S., Swystun, V.A., Bhagat, R., Cockroft, D.W. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996, 109: 953-6.
28. Yates, D.H., Kharitonov, S.A., Barnes, P.J. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta-agonist. Am J Respir Crit Care Med 1996, 154: 1603-7.
29. Cheung, D., Wever, A.M.J., de Goeij, J.A., de Graaff, C.S., Steen, H., Sterk, P.J. Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo. Am Respir Crit Care Med 1998, 158: 792-6.
30. Greening, A.P., Wind, P., Northfleld, M., Shaw, G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994, 344: 219-24.
31. Woolcock, A., Lundback, B., Ringdal, N., Jacques, L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996, 153: 1481-8.
32. Pauwels, R.A., Lofdahl, C.G., Postma, D.S, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997, 337: 1405-11.
33. Wilding, P., Clark, M., Thompson Coon, J. et al. Effect of long term treatment with salmeterol on asthma control: A double blind, randomized crossover study. Br Med J 1997, 314: 1441-6.
34. McIvor, R.A., Pizzichini, E., Turner, M.O., Hussack, P., Hargreave, F.E., Sears, M.R. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998, 158: 924-30.
35. Gardiner, P.V., Ward, C., Booth, H., Allison, A., Hendrick, D.J., Walters, E.H. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994, 150: 1006-11.
36. 2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997, 100: 261-5.
37. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993, 268: 23116-21.
38. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994, 33: 9414-9.
39. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995, 13: 25-33.
40. 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995, 345: 1213-4.
41. 2-agonist therapy in asthma. Eur Respir J 1998, 11: 589-93.
42. 2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997, 156: SI56-62.
43. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997, 100: 3184-8.
44. 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993, 8: 334-9.
45. 1 and FVC in Hutterites. Am J Respir Crit Care Med 1998, 157: A627.
46. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997, 350: 995-9.
47. 2-adrenergic receptor in nocturnal and non-nocturnal asthma. J Clin Invest 1995, 95: 1635-41.
48. 2-adrenergic receptor haplotypes in mild, moderate, and fatal/near fatal asthma. Am J Respir Crit Care Med 1998, 158: 787-91.
49. 2-adrenoceptor polymorphism and IgE variability in asthmatic families. Chest 1997, 111: 785-95.
50. 2-agonist in asthma: Effects on exacerbation and lung function. Br Med J 1998, 316: 664.
51. Weinberger, M., Hendeles, L. Theophylline. In: Allergy: Principles and Practice. E. Middleton, Jr., C.E. Reed, E.F. Ellis, N.F. Adkinson, Jr., J.W. Yunginger, W.W. Busse (Eds.). MosbyYear Book, Inc.: St. Louis 1993, 816-55.
52. Evans, D.J., Taylor, D.A., Zetterstrom, O., Chung, K.F., O'Connor, B.J., Barnes, P.J. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. New Engl J Med 1997, 337: 1412-8.
53. Kidney, J., Dominguez, M., Taylor, P.M., Rose, M., Chung, K.F., Barnes, P.J. Imunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995, 151: 1907-14.
54. Kraft, M., Torvik, J.A., Trudeau, J.B., Wenzel, S.E., Martin, R.J. Theophylline: Potential anti-inflammatory effects in nocturnal asthma. J Allergy Clin Immunol 1996, 97: 1242-6.
55. Hendeles, L., Weinberger, M., Szefler, S. Safety and efficacy of theophylline in children with asthma. J Pediatr 1992, 177-83.
56. Jusko, W.J., Gardner, M.J., Mangione, A., Schentag, J.J., Koup, J.R., Vance, J.W. Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci 1979, 68: 1358-66.
57. Furukawa, C.T., Shapiro, G.G., Bierman, C.W., Kraemer, M.J., Ward, D.J., Pierson, W.E. A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma. Pediatrics 1984, 453-9.
58. Rachelefsky, G.S., Wo, J., Adelson, J. et al. Behavior abnormalities and poor school performance due to oral theophylline use. Pediatrics 1986, 78: 1133-8.
59. Lindgren, S., Lokshin, B., Stromquist, A. et al. Does asthma or treatment with theophylline limit children's academic performance? New Engl J Med 1992, 327: 926-30.
60. Bender, B.G., Lerner, J.A., Ikle, D., Comer, C., Szefler, S. Psychological change associated with theophylline treatment of asthmatic children: A 6-month study. Pediatr Pulmonol 1991, 11: 233-44.
61. Bender, B., Milgrom, H. Theophylline-induced behavior change in children: An objective measure of parents' perceptions. JAMA 1992, 267: 2621-4.
62. Banner, K.H., Page, C.P. Theophylline and selective phosphodiesterase inhibitors as antiinflammatory drugs in the treatment of bronchial asthma. Eur Respir J 1995, 8: 996-1000.
63. Schudt, C., Tenor, H., Hatzelmann, A. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 1995, 8: 1179-83.
64. Gross, N.J., Skorodin, M.S. Anti-cholinergic, anti-muscarinic bronchodilators. Am Rev Respir Dis 1984, 129: 856-70.
65. Schuh, S., Johnson, D.W., Callahan, S., Canny, G., Levison, H. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr 1995, 126: 639-45.
66. Osmond, M.H., Klassen, T.P. Efficacy of ipratropium bromide in acute childhood asthma: A meta-analysis. Acad Emerg Med 1995, 2: 651-6.
67. Qureshi, F., Pestian, J., Davis, P., Zaritsky, A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New Engl J Med 1998, 339: 1030-5.
68. Karpel, J.P., Schacter, E.N., Fanta, C. et al. A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Chest 1996, 110: 611-6.
69. Ducharme, F.M., Davis, G.M. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma. J Pediatr 1998, 133: 479-85.
70. Rohr, A.S., Siegel, S.C., Katz, R.M., Rachelefsky, G.S., Spector, S.L., Lanier, R. A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. Ann Allergy 1987, 59: 107-9.
71. Petty, T.L., Rollins, D.R., Christopher, K., Good, J.T., Oakley, R. Cromolyn sodium is effective in adult chronic asthmatics. Am Rev Respir Dis 1989, 139: 694-701.
72. Hoag, I.E., McFadden, E.R., Jr. Long-term effect of cromolyn sodium on nonspecific bronchial hyperresponsiveness: A review. Ann Allergy 1991, 66: 53-63.
73. Schwartz, H.J., Blumenthal, M., Brady, R. et al. A comparative study of the clinical efficacy of nedocromil sodium and placebo. How does cromolyn sodium compare as an active control treatment? Chest 1996, 109: 945-52.
74. Brogden, R.N., Sorkin, E.M. Nedocromil sodium. An updated review of its pharmacologic properties and therapeutic efficacy in asthma. Drugs 1993, 45: 693-715.
75. Bel, E.H.I., Timmers, M.C., Hermans, J., Dijkman, J.H., Sterk, R.J. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990, 141: 21-8.
76. Shapiro, G.G., Sharpe, M., DeRouen, T.A. et al. Cromolyn versus triamcinalone acetonide for youngsters with moderate asthma. J Allergy Clin Immunol 1991, 88: 742-8.
77. Alton, E.W.F.W., Kingsleigh-Smith, D.J., Munkonge, F.M. et al. Asthma prophylaxis agents alter the function of an airway epithelial chloride channel. Am J Respir Cell Mol Biol 1996, 14: 380-7.
78. Konig, P. Clinical effects of nedocromil sodium on challenges invoking neuronal mechanisms and on virally induced symptoms. J Allergy Clin Immunol 1996, 98: SI35-40.
79. Loh, R.K., Jabara, H.H., Geha, R.S. Mechanisms of inhibition of IgE synthesis by nedocromil sodium: Nedocromil sodium inhibits deletional switch recombination in human B cells. Allergy Clin Immunol 1996, 97: 1141-50.
80. Lai, S., Dorow, P.D., Venho, K.K., Chatterjee, S.S. Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest 1993, 104: 438-47.
81. De Benedictis, F.M., Tuteri, G., Pazzelli, P., Bertotto, A., Bruni, L., Vaccaro, R. Cromolyn versus nedocromil: Duration of action in exercise-induced asthma in children. J Allergy Clin Immunol 1995, 96: 510-4.
82. Settipane, G.A., Klein, D.E., Boyd, G.K., Sturam, J.H., Freye, H.B., Weltman, J.K. Adverse reactions to cromolyn. JAMA 1979, 811-3.
83. Armenio, L., Baldini, G., Bardare, M. et al. Double-blind, placebo controlled study of nedocromil sodium in asthma. Arch Dis Child 1993, 68: 193-7.
84. Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A., Serhan, C.N. Leukotrienes and lipoxins: Structures, biosynthesis, and biologic effects. Science 1987, 237: 1171-6.
85. Horwitz, R.J., McGill, K.A., Busse, W.W. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998, 157: 1363-71.
86. Holgate, S.T., Bradding, P., Sampson, A.P. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J Allergy Clin Immunol 1996, 98: 1-13.
87. 4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998, 19: 453-61.
88. In, K.H., Asano, K., Beier, D. et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997, 99: 1130-7.
89. Meltzer, S.S., Hasday, J.D., Cohn, J., Bleecker, E.R. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996, 153: 931-5.
90. Israel, E., Fischer, A.R., Rosenberg, M.A. et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993, 148: 1447-51.
91. Israel, E., Cohn, J., Dube, L., Drazen, J.M. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 1996, 275: 931-6.
92. Tamaoki, J., Kondo, M., Sakai, N. et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroids. Am J Respir Crit Care Med 1997, 155: 1235-40.
93. Taylor, I., O'Shaughnessy, K., Fuller, R., Dollery, C. Effect of cysteinyl-leukotriene receptor antagonist ICI-204219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991, 337: 690-4.
94. Finnerty, J.P., Wood-Baker, R., Thomson, H., Holgate, S.T. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis 1992, 145: 746-9.
95. 4 antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1995, 150: 618-23.
96. Knorr, B., Matz, J., Bernstein, J.A. et al. Montelukast for chronic asthma in 6-to 14-year-old children. JAMA 1998, 279: 1181-6.
97. Altman, L.C., Munk, Z., Seltzer, J. et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol 1998, 102: 50-6.
98. Kemp, J.P., Dockhorn, R.J., Shapiro, G.G. et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-to 14-year-old children with asthma. J Pediatr 1998, 133: 424-8.
99. Left, J.A., Busse, W.W., Pearlman, D. et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New Engl J Med 1998, 339: 147-52.
100. Oosaki, R., Mizushima, Y., Kashii, T., Kawasaki, A., Kobayashi, M. Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. Int Arch Allergy Appl Immunol 1997, 114: 97-100.
101. Grossman, J., Faiferman, I., Dubb, J.W. et al. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997, 34: 321-8.
102. Barnes, N.C., Pujet, J.C. Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997, 52: 523-7.
103. Nakamura, Y., Hoshino, M., Sim, J.J., Ishii, K., Hosaka, K., Sakamoto, T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998, 53: 835-41.
104. Wechsler, M.E., Garpestad, E., Flier, S.R. et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998, 279: 455-7.
105. Knoell, D.L., Lucas, J., Allen, J.N. Churg-Strauss syndrome associated with zafirlukast. Chest 1998, 114: 332-4.
106. Schleimer, R.P. Glucocorticosteroids. Their mechanisms of action and use in allergic diseases. In: Allergy: Principles and Practice. E. Middleton, Jr., C.E. Reed, E.F. Ellis, N.F. Adkinson, Jr., J.W. Yunginger, W.W. Busse (Eds.). Mosby-Year Book, Inc.: St. Louis 1993, 893-925.
107. Barnes, P.J. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996, 154: 521-7.
108. Quinn, J.M. The side effects of inhaled corticosteroids. Insights Allergy 1994, 9: 1-8.
109. Konig, P. The risks and benefits of inhaled corticosteroids. Eur J Respir Dis 1993, 15: 501-10.
110. Allen, D.B., Mullen, M., Mullen, B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994, 93: 967-76.
111. Cumming, R.G., Mitchell, P., Leeder, S.R. Use of inhaled corticosteroids and the risk of cataracts. New Engl J Med 1997, 337: 8-14.
112. 2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992, 146: 547-54.
113. Connett, G., Lenney, W. Prevention of viral induced asthma attacks using inhaled budesonide. Arch Dis Child 1993, 68: 85-7.
114. Kamada, A.K., Szefler, S.J., Martin, R.J. et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996, 153: 1739-48.
115. Wolthers, O.D., Pedersen, S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child 1995, 68: 673-6.
116. Tinkelman, D.G., Reed, C.E., Nelson, H.S., Offord, K.P. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993, 92: 64-77.
117. Doull, I.J.M., Freezer, N.J., Holgate, S.T. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995, 151: 1715-9.
118. Verberne, A.A.P.H., Frost, C., Duiverman, E.J., G rol, M.H., Kerrebijn, K.F. and Dutch Pediatric Asthma Study Group. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med 1998, 158: 213-9.
119. Agertoft, L., Pedersen, S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994, 88: 373-81.
120. Allen, D.B., Bronsky, E.A., LaForce, C.F. et al. Growth in asthmatic children treated with fluticasone propionate. J Pediatr 1998, 132: 472-7.
121. Ferguson, A.C., Murray, A.B., Tze, W.-J. Short stature and delayed skeletal maturation in children with allergic disease. J Allergy Clin Immunol 1982, 69: 461-6.
122. Balfour-Lynn, L. Growth and childhood asthma. Arch Dis Child 1986, 61: 1049-55.
123. Lemanske, R.F. Jr., Allen, D.B. Choosing a long term controller medication in childhood asthma: The proverbial two-edged sword. Am J Respir Crit Care Med 1997, 156: 685-7.
124. Silverstein, M.D., Yunginger, J.W., Reed, C.E. et al. Attained adult height after childhood asthma: Effect of glucocorticoid therapy. J Allergy Clin Immunol 1997, 99: 466-74.
125. Kelly, H.W. Establishing a therapeutic index for inhaled corticosteroids: Part 1. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998, 102: S36-51.